KA/EN
Register
Medicines reference
Search
Search
Product

Antimed

Favourites

Atipamezole · Biotecsi Ltd

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
5 mg/ml, Solution · Cat Cat 0.04 ml/kg
Reverses medetomidine or dexmedetomidine. One injection into a muscle, 15-60 minutes after the sedative; may be repeated after 10-15 minutes if needed. The dose in micrograms/kg is 2.5 times the medetomidine dose, so the volume is half the volume of medetomidine 1 mg/ml (Imomedine) given: 0.04 ml/kg is the label example, 0.2 ml per 5 kg. After ketamine, not earlier than 30-40 minutes. Cats may become hypothermic.
 · once		 once Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: ანტიმედი
№ 000585
Verified on: 18 Oct 2026
5 mg/ml, Solution · Dog Dog 0.04 ml/kg
Reverses medetomidine or dexmedetomidine. One injection into a muscle, 15-60 minutes after the sedative; effect in 5-10 minutes; may be repeated after 10-15 minutes if needed. The dose in micrograms/kg is 5 times the medetomidine dose, so the volume equals the volume of medetomidine 1 mg/ml (Imomedine) given: 0.04 ml/kg is the label example, 0.4 ml per 10 kg. After medetomidine with ketamine the same dose, not earlier than 30-40 minutes after ketamine.
 · once		 once Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: ანტიმედი
№ 000585
Verified on: 18 Oct 2026
Details: pack, label wording, sources, registration

Antimed 5 mg/ml, Solution

atipamezole hydrochloride 5 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Reversal of medetomidine/dexmedetomidine sedative, analgesic, cardiovascular and respiratory effects in dogs, excluding ketamine-containing protocols
7.9/10
Good
vetman assessment

Antimed

5 mg/ml, atipamezole hydrochloride 5 mg/ml, solution for injection
Assessed clinical scopeDog · Reversal of medetomidine/dexmedetomidine sedative, analgesic, cardiovascular and respiratory effects in dogs, excluding ketamine-containing protocols · Intramuscular
Care settingMonitored veterinary recovery with the original alpha-2 drug, concentration, dose and combinations documented; quiet environment, continued haemodynamic/respiratory/temperature observation and re-sedation readiness
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 000585 · Verified on 18 Oct 2026

A credible, locally authorised and highly practical alpha-2 reversal product for documented medetomidine/dexmedetomidine protocols. Do not use it as a general antidote or to reverse a canine ketamine-containing protocol; recovery monitoring continues after awakening.

Regulatory and scientific credibility7.5/10

The exact 5 mg/ml 10 ml product has a current Georgian veterinary authorisation and a detailed manufacturer instruction covering composition, species, dose ratios, timing, safety and storage. Current VMD/EU same-strength controls are strong, but the exact instruction is not regulator-hosted, independent Antimed outcome data are absent and its canine ketamine wording conflicts with the recognised SPC.

Clinical efficacy8.5/10

Atipamezole is a highly specific and well-established antagonist with dose-response and modern haemodynamic evidence supporting rapid reversal after medetomidine/dexmedetomidine. It is not a general anaesthetic antidote and this assessment excludes canine ketamine combinations.

Safety and tolerability7.5/10

Adverse effects are usually transient, but early hypotension, tachycardia/over-alertness, vomiting, defecation, panting or tremor can occur. Awakening can precede full haemodynamic recovery and re-sedation remains possible, so monitoring must continue.

Clinical practicality8.5/10

A single IM injection, rapid expected arousal and equal-volume relation to preceding Imomedine 1 mg/ml are highly practical when the original protocol is documented. Ratio errors, canine ketamine exclusion, possible repeat and continued recovery observation remain essential checks.

Full-course cost-effectiveness-

A current Georgian clinic acquisition price and protocol-specific comparator cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Antimed is a specific antagonist for medetomidine or dexmedetomidine. It does not reverse ketamine, opioids, propofol, inhalants or unrelated sedatives and must not be treated as a general antidote.
  • Do not use Antimed to reverse a canine protocol containing ketamine. The local instruction permits delayed use, but the current recognised Antisedan SPC explicitly prohibits reversal of canine ketamine combinations; follow the safer higher-tier boundary.
  • Calculate from the actual preceding alpha-2 dose: atipamezole micrograms/kg = 5× medetomidine or 10× dexmedetomidine. Equal ml volume applies only to medetomidine 1 mg/ml or dexmedetomidine 0.5 mg/ml, not every product.
  • Document the original drug, concentration, route, time, dose and all combinations before reversal. A remembered brand colour or a fixed 0.04 ml/kg shortcut is unsafe when the preceding dose differed.
  • Awakening is not full recovery. Continue heart rate/rhythm, blood pressure, respiration/oxygenation, temperature and behaviour monitoring; haemodynamic recovery may lag and re-sedation can occur.
  • Transient hypotension may occur in the first 10 minutes; vomiting, defecation, panting and muscle tremor are reported. Allow recovery in a maximally quiet place and reassess perfusion rather than treating arousal alone as success.
  • If depression persists, repeat only after 10–15 minutes and after reassessing dose calculation, injection delivery, other anaesthetics, temperature, oxygenation and disease. More antagonist does not reverse non-alpha-2 drugs.
  • Overdose may cause temporary hyperactivity and tachycardia. Minimise external stimulation, provide quiet observation and treat clinically important cardiorespiratory effects rather than automatically adding more drugs.
  • Avoid in hypersensitivity and pregnancy/lactation; use cautiously in hepatic disease. Exact-product evidence in very young, geriatric or severely compromised patients is limited.
  • Store below 25°C in the original pack, protected from light and moisture, and discard 28 days after opening. Accidental self-injection can alter human alertness and cardiovascular function and requires urgent medical assessment.
Assessment sources
  1. Antimed exact instruction2026
  2. VMD SPC 20252025
  3. Antisedan UPD control2026
  4. Dog atipamezole dose-response trial1990
  5. Dog atipamezole haemodynamic trial2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Reversal of medetomidine/dexmedetomidine sedative, analgesic, cardiovascular and respiratory effects in cats, including correctly timed recovery after supported ketamine combinations
7.7/10
Good
vetman assessment

Antimed

5 mg/ml, atipamezole hydrochloride 5 mg/ml, solution for injection
Assessed clinical scopeCat · Reversal of medetomidine/dexmedetomidine sedative, analgesic, cardiovascular and respiratory effects in cats, including correctly timed recovery after supported ketamine combinations · Intramuscular
Care settingMonitored veterinary recovery with the original alpha-2 drug, concentration, dose and combinations documented; quiet environment, continued haemodynamic/respiratory/temperature observation and re-sedation readiness
vetman score 7.7/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · № 000585 · Verified on 18 Oct 2026

A credible, locally authorised and practical feline alpha-2 reversal product with direct clinical support. Its value depends on the correct dose ratio, ketamine delay, active warming and continued observation after rapid arousal.

Regulatory and scientific credibility7.5/10

The exact 5 mg/ml 10 ml product has a current Georgian veterinary authorisation and a detailed manufacturer instruction covering composition, species, dose ratios, timing, safety and storage. Current VMD/EU same-strength controls are strong, but the exact instruction is not regulator-hosted, independent Antimed outcome data are absent and its canine ketamine wording conflicts with the recognised SPC.

Clinical efficacy8.5/10

A blinded multicentre feline trial and current regulatory labels support rapid reversal of sedation/analgesia, heart-rate recovery and limitation of further respiratory-rate/temperature decline. Effect depends on correct alpha-2 dose ratio and ketamine timing.

Safety and tolerability7.0/10

Hypothermia may persist despite awakening; over-alertness/tachycardia can follow overdose and early post-ketamine reversal can provoke convulsions. Continued warming, quiet recovery and monitoring are required even when righting returns rapidly.

Clinical practicality8.0/10

A single IM injection, rapid expected arousal and half-volume relation to preceding Imomedine 1 mg/ml are practical. Small-volume accuracy, mandatory ketamine delay, active warming and continued monitoring add manageable clinical work.

Full-course cost-effectiveness-

A current Georgian clinic acquisition price and protocol-specific comparator cost were not verified; price is excluded from the denominator.

Important safety and use flags

  • Antimed is a specific antagonist for medetomidine or dexmedetomidine. It does not reverse ketamine, opioids, propofol, inhalants or unrelated sedatives and must not be treated as a general antidote.
  • After a ketamine-containing feline protocol, wait at least 30–40 minutes after ketamine before atipamezole. Earlier alpha-2 reversal can leave unopposed ketamine and provoke convulsions.
  • Calculate from the actual preceding alpha-2 dose: atipamezole micrograms/kg = 2.5× medetomidine or 5× dexmedetomidine. Half ml volume applies only to medetomidine 1 mg/ml or dexmedetomidine 0.5 mg/ml, not every product.
  • Document the original drug, concentration, route, time, dose and all combinations before reversal. A remembered brand colour or a fixed 0.04 ml/kg shortcut is unsafe when the preceding dose differed.
  • Awakening is not full recovery. Continue heart rate/rhythm, blood pressure, respiration/oxygenation, temperature and behaviour monitoring; haemodynamic recovery may lag and re-sedation can occur.
  • Continue active temperature monitoring and warming. Feline hypothermia may persist after partial reversal even when the cat is awake and able to stand.
  • If depression persists, repeat only after 10–15 minutes and after reassessing dose calculation, injection delivery, other anaesthetics, temperature, oxygenation and disease. More antagonist does not reverse non-alpha-2 drugs.
  • Overdose may cause temporary hyperactivity and tachycardia. Minimise external stimulation, provide quiet observation and treat clinically important cardiorespiratory effects rather than automatically adding more drugs.
  • Avoid in hypersensitivity and pregnancy/lactation; use cautiously in hepatic disease. Exact-product evidence in very young, geriatric or severely compromised patients is limited.
  • Store below 25°C in the original pack, protected from light and moisture, and discard 28 days after opening. Accidental self-injection can alter human alertness and cardiovascular function and requires urgent medical assessment.
Assessment sources
  1. Antimed exact instruction2026
  2. VMD SPC 20252025
  3. Antisedan UPD control2026
  4. Feline dexmedetomidine-atipamezole trial2006
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Atipamezole5 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Manufacturer
Biotecsi Ltd · Georgia
Manufacturer (register)
Biotecsi Ltd, Georgia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1042, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 09 Apr 2029
Veterinary (National Food Agency)
In the register: ანტიმედი
№ 000585
Verified on: 18 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified IM once, normally 15–60 minutes after medetomidine/dexmedetomidine; expected reversal begins in 5–10 minutes. Dog: atipamezole microgram dose is 5× the preceding medetomidine dose; with 5 mg/ml Antimed after 1 mg/ml Imomedine, the ml volume is equal (label example 0.4 ml/10 kg). Cat: 2.5× the medetomidine dose; the Antimed ml volume is half the Imomedine volume (example 0.2 ml/5 kg). Repeat after 10–15 minutes only if depression persists and the original drug, concentration, dose, combinations and physiology have been reassessed. These are dose relationships, not a universal fixed volume.
DoseSpeciesWeightRouteFrequencySource
0.04 ml/kg
Reverses medetomidine or dexmedetomidine. One injection into a muscle, 15-60 minutes after the sedative; may be repeated after 10-15 minutes if needed. The dose in micrograms/kg is 2.5 times the medetomidine dose, so the volume is half the volume of medetomidine 1 mg/ml (Imomedine) given: 0.04 ml/kg is the label example, 0.2 ml per 5 kg. After ketamine, not earlier than 30-40 minutes. Cats may become hypothermic.
 Cat Any weight Intramuscular once
Antimed exact instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Antimed 0.5% (atipamezole hydrochloride 5 mg/ml) solution for injection - exact manufacturer instruction
Biotecsi, 2026
0.04 ml/kg
Reverses medetomidine or dexmedetomidine. One injection into a muscle, 15-60 minutes after the sedative; effect in 5-10 minutes; may be repeated after 10-15 minutes if needed. The dose in micrograms/kg is 5 times the medetomidine dose, so the volume equals the volume of medetomidine 1 mg/ml (Imomedine) given: 0.04 ml/kg is the label example, 0.4 ml per 10 kg. After medetomidine with ketamine the same dose, not earlier than 30-40 minutes after ketamine.
 Dog Any weight Intramuscular once
Antimed exact instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Antimed 0.5% (atipamezole hydrochloride 5 mg/ml) solution for injection - exact manufacturer instruction
Biotecsi, 2026

Known Contraindications

  • Critical
    Do not use in animals hypersensitive to atipamezole or to the excipients (methyl parahydroxybenzoate).
  • Warning
    Safety in pregnancy and lactation has not been established; use is not recommended.
  • Warning
    Safety in pregnancy and lactation has not been established; use is not recommended.
  • Caution
    Ketamine: in dogs do not use atipamezole to reverse a combination that included ketamine; in cats do not give it within 30-40 minutes of ketamine, as the remaining ketamine effect may cause convulsions. Let the animal recover somewhere quiet; dogs may have transient low blood pressure in the first 10 minutes.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗